Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2014 06:01 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Announces Publication of Meta-Analysis From the Global PBC Study Group in Gastroenterology

- Largest Analysis of Data from Patients with Primary Biliary Cirrhosis - Alkaline Phosphatase (ALP) and Bilirubin Shown to Significantly Predict Clinical Outcomes NEW YORK, Dec. 5, 2014...
November 25, 2014 06:05 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at Upcoming Investor Conferences

NEW YORK, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
November 17, 2014 06:01 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Appoints Lisa Bright as Head of Europe

NEW YORK and LONDON, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel...
November 08, 2014 08:01 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Announces Additional Data for OCA in Primary Biliary Cirrhosis

NEW YORK, Nov. 8, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
November 06, 2014 19:05 ET | Source: Intercept Pharmaceuticals, Inc.

FLINT Trial in NASH Published in The Lancet

-OCA meets primary endpoint with high statistical significance of p=0.0002 -First therapeutic NASH trial to show significant improvement in liver fibrosis - Investor conference call and...
November 06, 2014 17:28 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Business Updates

NEW YORK, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
October 31, 2014 06:01 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Report Third Quarter 2014 Results on November 7 and Present at Upcoming Conferences

NEW YORK, Oct. 31, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
October 08, 2014 06:30 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Announces Data to be Presented at the 2014 AASLD Annual Meeting

NEW YORK, Oct. 8, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel...
September 12, 2014 06:55 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Recognizes International PBC Day

NEW YORK, Sept. 12, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel...
August 26, 2014 08:05 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at Upcoming Investor Conferences

NEW YORK, Aug. 26, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...